Literature DB >> 1401749

Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.

R Tedde1, A Pala, A Melis, S Ulick.   

Abstract

The hypothesis that cortisol is the functioning mineralocorticoid in the syndrome of apparent mineralocorticoid excess was tested by suppressing its secretion with dexamethasone. The subjects were two siblings with the type 2 form of this syndrome in which the defect in the peripheral metabolism of cortisol lies predominantly in ring A reduction but not in 11 beta-hydroxy dehydrogenation of cortisol to cortisone. Low dosage dexamethasone improved the hypokalemia within several days and hypertension was corrected after 3 weeks of treatment. Mineralocorticoid manifestations remained in remission during 10 yr of therapy with the synthetic glucocorticoid during which normal growth and development were restored. The effectiveness of dexamethasone supports the hypothesis that cortisol is the functioning mineralocorticoid in the AME syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401749     DOI: 10.1007/BF03348778

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  13 in total

1.  Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess.

Authors:  S Ulick; R Tedde; J Z Wang
Journal:  J Clin Endocrinol Metab       Date:  1992-03       Impact factor: 5.958

2.  Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess.

Authors:  S Ulick; R Tedde; F Mantero
Journal:  J Clin Endocrinol Metab       Date:  1990-01       Impact factor: 5.958

3.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.

Authors:  J L Arriza; C Weinberger; G Cerelli; T M Glaser; B L Handelin; D E Housman; R M Evans
Journal:  Science       Date:  1987-07-17       Impact factor: 47.728

4.  Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated.

Authors:  J W Funder; P T Pearce; R Smith; A I Smith
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

5.  Fatal, low renin hypertension associated with a disturbance of cortisol metabolism.

Authors:  J W Honour; M J Dillon; M Levin; V Shah
Journal:  Arch Dis Child       Date:  1983-12       Impact factor: 3.791

6.  A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol.

Authors:  S Ulick; L S Levine; P Gunczler; G Zanconato; L C Ramirez; W Rauh; A Rösler; H L Bradlow; M I New
Journal:  J Clin Endocrinol Metab       Date:  1979-11       Impact factor: 5.958

7.  Low-renin, low-aldosterone hypertension and abnormal cortisol metabolism in a 19-month-old child.

Authors:  T J Fiselier; B J Otten; L A Monnens; J W Honour; P J van Munster
Journal:  Horm Res       Date:  1982

8.  Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess.

Authors:  S E Oberfield; L S Levine; R M Carey; F Greig; S Ulick; M I New
Journal:  J Clin Endocrinol Metab       Date:  1983-02       Impact factor: 5.958

9.  Apparent mineralocorticoid excess and deficient 11 beta-oxidation of cortisol in a young female.

Authors:  H I Harinck; P van Brummelen; A P Van Seters; A J Moolenaar
Journal:  Clin Endocrinol (Oxf)       Date:  1984-11       Impact factor: 3.478

10.  Unusual low plasma renin hypertension in a child.

Authors:  L Sann; A Revol; M Zachmann; J C Legrand; M Bethenod
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

View more
  2 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

2.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.